| |
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now!
|
|
Today’s Big NewsOct 11, 2024 |
|
De-risk clinical trials with Foresight CLARITY’s ultra-sensitive MRD detection. Foresight CLARITY is IUO-ready for prospective trials through our CLIA-registered central lab. Learn more about Foresight CLARITY™️.
|
|
| By Kevin Dunleavy For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi, an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B. |
|
|
|
By James Waldron The U.S. drugmaker has “mutually agreed” to terminate its collaboration and license agreement with South Korean biotech Yuhan for a pair of MASH therapies. |
By Nick Paul Taylor Sanofi has stopped a phase 2 trial of the Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after failing to meet its primary and secondary endpoints, dealing a further blow to a collaboration with a troubled history. |
By Angus Liu As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2-billion-Swiss-francs luster to the once high-flying portfolio. |
|
| Wednesday, October 16, 2024 | 2pm ET / 11am PTJoin experts as they delve into the distinct strategies required for developing ADCs and RIT, focusing on how medical imaging can accelerate clinical trials and drug approval. Register now to gain practical insights into optimizing clinical trials and advancing cancer therapies through cutting-edge imaging techniques.
|
|
By Kevin Dunleavy Five months after Eli Lilly secured the first of two approvals for tirzepatide in China, the company has revealed that it will invest $200 million to expand its manufacturing site in Suzhou to produce the in-demand drugs. |
By Gabrielle Masson Difficult. Impossible. Agonizing. Worse than voting in the national election. All those descriptors were used today by FDA advisory committee members when asked to vote on an investigational rare disease therapy. |
By Nick Paul Taylor A survey of more than 2,000 patients and physicians has painted a rosy picture of the impact of pharma ads, showing that promotions raise awareness of treatment options, drive discovery of health conditions and improve management of existing ailments. |
By Darren Incorvaia,Zoey Becker Eli Lilly is ramping up its efforts to incorporate AI across its business by appointing Thomas Fuchs to the new role of chief AI officer. In his new job, Fuchs will lead AI initiatives across Lilly’s drug discovery, clinical trials, manufacturing, commercial activities and internal functions. |
By Zoey Becker The agency flagged multiple observations at the company's Patheon CDMO subsidiary's Greenville, North Carolina, plant after a May inspection. |
By Andrea Park A new campaign from Opella, Sanofi’s consumer health unit, is a royal flush. |
By Conor Hale Abbott received an FDA clearance for the latest version of its sensor-laden catheter to map out the heart's electrical activity, which will help support its upcoming ablation devices for afib. |
By Andrea Park A year after Pinterest first began allowing advertisements from prescription drugmakers and prescribers, Publicis Health Media has accumulated several tips and tricks for pharmas seeking success on the platform. |
By Conor Hale Bruker has formed a new, single division out of the various spatial biology assets it has acquired over the years. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," Fierce Pharma's Fraiser Kansteiner chats with industry leaders about the surge in neuroscience investment, breakthroughs and future targets in neuropharmaceuticals. |
|
|---|
|
|
|
Wednesday, October 23, 2024 | 11am ET / 8am PT Large, deeply characterized patient cohorts are one of the most promising data resources today for understanding disease biology and developing new medicines. Join us as we explore how this data is driving the next generation of pharmaceutical development. Learn how to leverage genetic research in today's highly competitive landscape. Register now.
|
|
| eBookNeed the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
| WhitepaperWhen the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
| WhitepaperPower non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
